Full Text View
Tabular View
No Study Results Posted
Related Studies
Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression
This study has been completed.
Study NCT00518479   Information provided by University of Leeds
First Received: August 17, 2007   Last Updated: August 21, 2007   History of Changes

August 17, 2007
August 21, 2007
September 2003
 
The primary outcome measure is decrease in LV mass as assessed by cardiac MRI compared between the two treatment groups. [ Time Frame: 6 months ]
Same as current
Complete list of historical versions of study NCT00518479 on ClinicalTrials.gov Archive Site
 
 
 
Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression
Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression

Uncontrolled high blood pressure can cause heart muscle 'thickening', and this increases the likelihood of complications and death. The high blood pressure explains some but not all of this increase in heart size. This study will investigate the other causes, and will measure the heart muscle 'thickness' very accurately using the latest and most accurate technique called cardiac magnetic resonance imaging (MRI). The best way to treat this heart thickening remains to be determined. We hope to be able to show that by specifically targeting the cause of heart muscle thickening we can reduce its occurrence more effectively than by other standard means of blood pressure treatment

 
 
Interventional
Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
  • Hypertension
  • Left Ventricular Hypertrophy
  • Drug: Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD
  • Drug: Valsartan 160mg OD; Moxonidine 400mcg OD
  • Experimental: Neurohormonal stimulatory arm
  • Experimental: Neurohormonal inhibitory arm
Burns J, Sivananthan MU, Ball SG, Mackintosh AF, Mary DA, Greenwood JP. Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation. 2007 Apr 17;115(15):1999-2005. Epub 2007 Mar 26.

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
42
April 2004
 

Inclusion Criteria:

  • Recently diagnosed essential hypertension (within 6 months).
  • Age 25 to 80 years; Weight < 100kg.
  • Sinus rhythm without significant ventricular or atrial ectopy.

Exclusion Criteria:

  • Current angiotensin II receptor antagonist or ACE Inhibitor treatment.
  • Contra-indication to any of the protocol anti-hypertensive agents.
  • Angina requiring treatment with a Beta blocker or calcium antagonist
  • Any disease affecting the autonomic nervous system e.g. congestive cardiac failure, diabetes, neurological disease, malignancy, pregnancy.
  • Contraindication to MRI (pacemaker, intra-orbital debris, intra-auricular implants, intra-cranial clips, history of claustrophobia, inability to lie supine for 15 minutes etc).
Both
25 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT00518479
 
PG/03/001
University of Leeds
The Leeds Teaching Hospitals NHS Trust
Principal Investigator: John P Greenwood, MBChB, PhD, MRCP Leeds University
University of Leeds
August 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP